Welcome to our dedicated page for SANGAMO THERAPEUTICS SEC filings (Ticker: SGMOQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SANGAMO THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SANGAMO THERAPEUTICS's regulatory disclosures and financial reporting.
Sangamo Therapeutics, Inc. describes progress in its Chapter 11 case and its Nasdaq listing status. After filing for voluntary Chapter 11 relief on June 23, 2026, the Delaware bankruptcy court approved Bidding Procedures on July 14, 2026 for a potential sale of all or substantially all assets.
The order sets a bid deadline of August 4, 2026, a potential auction on August 10, 2026, and a sale hearing on August 20, 2026, while the company operates as a debtor-in-possession seeking to maximize stakeholder value. On the same date, a Nasdaq Hearings Panel denied continued listing, and the company expects Nasdaq to file Form 25 to complete delisting as its shares trade on the OTCID Basic Market under the symbol SGMOQ.